Correction Issued for GDP-Mannose Triple-Negative Breast Cancer Study
Science Translational Medicine publishes an erratum for a 2024 study on GDP-mannose and antitumor immunity in triple-negative breast cancer.
Summary
Science Translational Medicine has issued a formal erratum correcting the 2024 research article examining guanosine diphosphate-mannose (GDP-mannose) as a potential therapeutic agent in triple-negative breast cancer (TNBC). The original study investigated how GDP-mannose suppresses homologous recombination DNA repair pathways in cancer cells and simultaneously enhances antitumor immune responses. The erratum does not constitute a retraction; it is a correction to specific elements of the published work. The underlying research explored a novel metabolic approach to sensitizing TNBC — one of the most aggressive and difficult-to-treat breast cancer subtypes — to immune-mediated killing. Readers should consult the corrected version of the original article before citing or applying its findings clinically or in further research.
Detailed Summary
Triple-negative breast cancer (TNBC) remains one of the most lethal breast cancer subtypes, lacking estrogen receptor, progesterone receptor, and HER2 targets that guide treatment in other forms of the disease. This makes identifying novel vulnerabilities — metabolic, immunological, or genomic — especially urgent.
The original 2024 paper published in Science Translational Medicine explored a striking hypothesis: that guanosine diphosphate-mannose (GDP-mannose), a nucleotide sugar involved in glycosylation pathways, could disrupt homologous recombination (HR) repair in cancer cells. HR repair is a key mechanism by which tumors evade DNA-damaging therapies. By impairing this pathway, GDP-mannose could render TNBC cells more vulnerable to genomic instability while simultaneously stimulating antitumor immune responses.
The implications of the original findings were significant. If GDP-mannose suppresses HR repair, it could function synergistically with PARP inhibitors or immunotherapies — treatment classes already showing promise in TNBC. The dual action of sensitizing cancer cells while activating immune attack represents a compelling therapeutic rationale.
This July 2026 publication is an erratum — a formal correction to the original article — not a retraction. The specific nature of the error is not detailed in the erratum abstract. Errata can range from figure labeling errors to data corrections, and the scientific weight of the original conclusions may or may not be substantially affected.
Researchers, clinicians, and oncologists who have cited or intend to apply findings from the original study (Sci Transl Med. 2024 Jan 3;16(728):eadg7740) should review the corrected version carefully. The corrected article remains the authoritative reference for GDP-mannose research in TNBC.
Key Findings
- An erratum has been issued for the 2024 GDP-mannose TNBC study in Science Translational Medicine.
- The original study found GDP-mannose suppresses homologous recombination repair in triple-negative breast cancer cells.
- The original research also reported GDP-mannose potentiates antitumor immune responses in TNBC models.
- The erratum is a correction, not a retraction; the original paper remains in the literature with amendments.
- Researchers citing the original study should consult the corrected version before further use.
Methodology
This publication is an erratum notice, not a primary study. The original research article (eadg7740, January 2024) examined GDP-mannose effects on DNA repair and immune responses in TNBC; specific methods, models, and experimental details are described in that source. The erratum abstract provides no information about the nature or scope of the correction.
Study Limitations
This summary is based on the erratum abstract only, which contains no detail about what was corrected in the original paper. The scientific validity and magnitude of the original findings cannot be assessed from this notice alone. Full review of both the corrected article and the erratum is required for accurate interpretation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: